Fig. 8: Model that illustrates pathways in response to Dasatinib and CmpdA treatment in cisplatin resistant-HNSCC cells. | Cell Death Discovery

Fig. 8: Model that illustrates pathways in response to Dasatinib and CmpdA treatment in cisplatin resistant-HNSCC cells.

From: Inhibition of IKKβ/NF-κB signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma

Fig. 8

Dasatinib inhibited SRC activity and lowered ETS-1 expression, but induced the IKK/NF-κB pathway, while the IKKβ inhibitor CmpdA blocked Dasatinib induction of IKK/NF-κB. A combination of Dasatinib and CmpdA led to significant inhibition of ETS-1 and IKK/NF-κB as well as cell proliferation and survival.

Back to article page